This trial is evaluating whether RelieVRx headset will improve 2 primary outcomes and 8 secondary outcomes in patients with Pain, Postoperative. Measurement will happen over the course of 1 day.
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. RelieVRx Headset is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Pain is a common and significant issue for an operation. In this country, only 25% of patients have postoperative pain managed appropriately. However, in most cases, the pain is treated on site when appropriate.
Almost half of Americans in the United States (48.5%) report they had postoperative pain one year after surgical procedures in 2010. About 13 million Americans report postoperative pain in 1 to 6 day postoperative period. The current study suggests nearly half of patients (46.2%) report pain for postoperative period that begins the following day postoperatively and extends to the 1-year postoperative period.
Pain is not always obvious and can be subtle in the early postoperative period, especially if there were previous surgeries. Pain typically worsens at night and improves in the wake of light or sound. It can be hard to tell the difference between shoulder or low [back pain](https://www.withpower.com/clinical-trials/back-pain). In most cases, it is possible to obtain information to assist in making the diagnosis. If the pain persists for longer than one or two days, then follow-up visits will be necessary.
There are a number of effective treatments for a variety of postoperative pain. The American Pain Society has published recommended practice guidelines on postoperative pain. For postoperative pain, opioids are commonly used and are effective.
Pain following surgery is often a functional experience, in which the patient learns to use compensating strategies in response to pain. Pain in the early phase after surgery may be due to normal physiological responses, and, given that these responses diminish as time passes after surgery, this pain may be interpreted as a pathology, as may be the case for post-operative pain seen in chronically ill patients. The latter is often thought to be due to neuropathic pain. Such an interpretation often ignores the importance of interactions with the patient and the family, which can lead to distress and pain-related distress.
Findings from a recent study indicate that in this study cohort, none of the observed associations corresponded to any previously described genetic contribution. As pain, postoperative run in families share common genetic etiology with chronic postoperative pain, the associations reported here could reflect a common etiology for both diseases.
Pain may be caused by a variety of factors, in which psychologic factors, pain perception and processing, neuroanatomy, and pain management are important in this area. Clinicians must evaluate all factors in the postoperative patient carefully in a multidisciplinary setting. Appropriate use of pain management can reduce postoperative pain in otherwise healthy patients.
Asking for a second opinion from a qualified expert can be very useful. Relieving symptoms post-surgery may be the least important aspect of treatments for chronic post-surgical pain.
In most instances, the combination used was the relievrx headset with an opioid medication. Because these combinations are very common, clinicians may need to be reminded of their clinical practice when these combinations are used. Therefore, we recommend that clinicians should be aware that these combinations may be a potential opioid interaction in patients with painful postsurgical conditions. Patient education would be a helpful adjunct to this consideration, and a proper informed consent should be obtained.
There is no significant evidence to suggest that the use of the Relivex or Relivex 1 is effective in managing various types of acute-onset headache. Relivex can alleviate moderate to severe pain of short duration in patients who are taking NSAIDS for migraine prophylaxis. Relivex has been shown to be effective in relieving mild pain (short period of 1 to 4 days) in patients with chronic pain.